Despite concerns about the development of secondary T-cell malignancies due to CAR T-cell immunotherapy, experts still believed that the benefits outweigh the risks.
Wider availability of cheaper CAR-T cell therapy or engineering immune cells to treat blood cancer and a government HPV vaccination programme will be among the key breakthroughs
Infections, cardiopulmonary disease, and second cancers were among the leading causes of nonrelapse deaths in patients receiving CAR T-cell therapy, both in clinical trials and clinical practice.
CAR T cells directed against the B-cell maturation antigen (BCMA) are linked to systemic and neurological side effects, while the antibody teclistamab is associated with increased infection risk.
'In patients with relapsed DLBCL in a complete remission, treatment with auto-HCT is associated with a lower rate of relapse/progression, and a longer progression-free survival [versus CAR T therapy].'